A routine measurement hiding in standard blood work may reveal who will develop Alzheimer's disease long before memory problems surface. Researchers at NYU Langone Health found that the balance between two types of immune cells, tracked through a simple calculation called the neutrophil to lymphocyte ratio, showed a striking link to dementia risk across nearly 400,000 patients.
The neutrophil to lymphocyte ratio, or NLR, measures the proportion of neutrophils (infection-fighting white blood cells) against lymphocytes (another type of immune cell). It is already routinely calculated from complete blood counts, the same tests doctors order to check for infections or assess immune function. The finding means hospitals and clinics already have the raw data to flag at-risk patients without needing new or costly screening tools.
The research, published in Alzheimer's and Dementia in April, tracked patients from four NYU Langone hospitals and the Veterans Health Administration. Researchers examined the earliest qualifying NLR measurement for each person, taken before any diagnosis of Alzheimer's or other dementia, then followed whether those individuals developed cognitive decline during the study period.
Across both patient populations, the pattern was consistent: higher NLR readings predicted increased dementia risk in both the near and long term. The relationship held even when researchers defined high NLR based on the median value in the study population. The findings were particularly pronounced in Hispanic patients and women, though scientists are still working to understand whether genetics, healthcare access, or other factors account for the difference.
Neutrophils are the body's rapid-response immune cells, firing up quickly when infection or inflammation is detected. Under normal circumstances they are essential fighters against pathogens and tissue repair agents. But in the wrong context, they can also cause damage, particularly in blood vessels and brain tissue. Studies of Alzheimer's patients have found signs of neutrophil-driven inflammation in affected brains, and animal research suggests these cells can accelerate disease progression.
The question driving the next phase of research is whether neutrophils are merely a marker of Alzheimer's developing, or whether they actively fuel disease progression. That distinction matters enormously for treatment. If neutrophils are actively causing damage, they become a potential drug target.
Dr. Jaime Ramos-Cejudo, one of the study's senior authors, emphasized that an elevated NLR alone is unlikely to serve as a definitive Alzheimer's diagnosis. Instead, when combined with other known risk factors, it could help doctors identify people who need closer monitoring, additional testing, or early interventions before cognitive decline appears. The goal is to catch at-risk patients in a window where prevention or early treatment might make a difference.
One complication in future research is the short lifespan of neutrophils themselves. Unlike other cell types that can be stored for later study, neutrophils must be analyzed from fresh blood samples, making certain types of research logistically challenging. Researchers have also not yet proven that neutrophil elevation directly causes dementia, only that the two are associated.
The research team is now pursuing more detailed investigation of whether neutrophils actively contribute to cognitive decline by combining neutrophil measurements with advanced brain imaging like PET scans and diffusion MRI, along with formal cognitive assessments. If those studies confirm an active mechanism, it could reshape how doctors screen for and treat Alzheimer's risk years before symptoms appear.
Author Jessica Williams: "This is the kind of finding that could actually move the dial on early detection, but only if clinicians start paying attention to a number that's already on every blood work panel."
Comments